In this article, we deep dive into the 5 Stocks Racking Up Monster Gains. For a deeper discussion and an extended list, please see 10 Stocks Racking Up Monster Gains.
Photo by Tima Miroshnichenko on Pexels
5. Cleveland-Cliffs Inc. (NYSE:CLF)
Shares of Cleveland-Cliffs jumped by 8.71 percent on Monday to finish at $10.61 apiece, as investors loaded portfolios in high-growth industries, with optimism supported by the US and Iran’s plan to end the war.
Cleveland-Cliffs Inc. (NYSE:CLF)—a US-based steel producer—has been attracting investor attention recently, supported by its efforts to diversify into the rare earths sector.
Last year, Cleveland-Cliffs Inc. (NYSE:CLF) announced that it officially kicked off efforts to expand beyond steelmaking and into rare earth mining, with the potential of two mining sites in Michigan and Minnesota being explored at present.
“If successful, it would align Cleveland-Cliffs with the broader national strategy for critical material independence, similar to what we achieved in steel. American manufacturing shouldn’t rely on China or any foreign nation for essential minerals, and Cliffs intends to be part of the solution,” Goncalves said.
Rare earth mining is one of the highly-prioritized industries identified by President Donald Trump, in line with his goals to reduce the United States’ reliance on China for rare earths.
In other news, Cleveland-Cliffs Inc. (NYSE:CLF) said last week that it narrowed its net loss attributable to shareholders by 52.4 percent to $237 million from $498 million in the same period last year. Revenues increased by 6 percent to $4.9 billion from $4.6 billion year-on-year.
4. Uranium Energy Corp. (NYSEAmerican:UEC)
Uranium Energy grew its share prices by 9.68 percent on Monday to finish at $15.41 apiece, as investor optimism was fueled by the improving macroeconomic conditions after the US and Iran hinted at ending the war.
In other news, Uranium Energy Corp. (NYSEAmerican:UEC) recently secured the approval of the Texas Commission on Environmental Quality (TCEQ) for its Buke Hollow project, paving the way for the commencement of operations.
Uranium Energy Corp. (NYSEAmerican:UEC) said that the development will be the first in-situ recovery uranium to be operating in over a decade.
Production will be processed at the Hobson Central Processing Plant, which is licensed to produce up to 4 million pounds of uranium per year.
“The startup of Burke Hollow is a significant achievement for UEC, advancing the project from a grassroots discovery in 2012 to production in 2026. With two ISR operations now producing, and our Ludeman ISR project planned for startup in 2027, we are building a scalable, multi-faceted platform supported by the largest uranium resource base in the United States,” said Uranium Energy Corp. (NYSEAmerican:UEC) President and CEO Amir Adnani.
“Our 100 percent unhedged, staged production growth strategy positions UEC to meet strengthening market fundamentals and growing U.S. policy support for the domestic nuclear fuel supply chain,” he added.
3. Oruka Therapeutics Inc. (NASDAQ:ORKA)
Oruka Therapeutics soared to a new record high on Monday, as investors positioned portfolios following positive results from the clinical study of its psoriasis treatment candidate, ORKA-001.
In an updated report, Oruka Therapeutics Inc. (NASDAQ:ORKA) said that 40 of the 63 enrolled patients treated with ORKA-001 achieved the primary endpoint of PASI 100 at Week 16, representing a complete skin clearance.
Based on a cross-trial comparison, ORKA-001 demonstrated numerically higher rates of skin clearance than all other IL-23p19 inhibitors.
Additionally, ORKA-001 recorded a safety profile and recorded no serious treatment-emergent adverse effects.
Following the news, shares of Oruka Therapeutics Inc. (NASDAQ:ORKA) climbed to their highest price of $91 in intra-day trading on Monday before paring gains to finish the session just up by 10.66 percent at $76.39 apiece.
“These data reached the top end of what we could have expected from ORKA-001 across efficacy, tolerability, and potential for long-lasting response,” Oruka Therapeutics Inc. (NASDAQ:ORKA) Chief Medical Officer Joana Goncalves said.
“We’re thrilled with the profile that is emerging for this program and are excited to see how the data matures with longer-term follow-up,” she added.
Longer-term data from the study, covering 28 weeks of treatment, is set to be provided in the second half of the year.
2. Organon & Co. (NYSE:OGN)
Organon soared to a new 52-week high on Monday, as investors gobbled up shares after the company officially confirmed its planned $11.75-billion merger with Sun Pharmaceuticals.
In intra-day trading, the stock climbed to its highest price of $13.24 before trimming gains to finish the session just up by 16.87 percent at $13.16 apiece.
In a joint statement, Organon & Co. (NYSE:OGN) said that Sun Pharma is set to acquire all its outstanding shares at $14 apiece, in an all-cash transaction, in line with the latter’s strategy of growing its innovative medicines business.
The transaction officially secured the green light of both firms’ board of directors and is now up for approval by the shareholders.
“Following a comprehensive review of strategic alternatives, our board determined that this all‑cash transaction offers compelling and immediate value to Organon stockholders. We believe Sun Pharma is well-positioned to support Organon’s businesses, employees, and patients globally, and to further advance our commitment to delivering impactful medicines and solutions,” said Organon & Co. (NYSE:OGN) Executive Chairman Carrie Cox.
The transaction is expected to close in early 2027, subject to other customary closing conditions.
Organon & Co. (NYSE:OGN) is a global leader in women’s health. It was formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021.
1. X-Energy Inc. (NASDAQ:XE)
X-Energy soared higher in its second day as a publicly listed company, climbing 23.22 percent to close at $35.98 apiece on Monday, as investors resumed buying positions amid the rosy prospects for the nuclear sector.
Last Friday, X-Energy Inc. (NASDAQ:XE) debuted on the stock market, successfully raising $1.017 billion in fresh funds from the sale of 44.2 million Class A shares. As of Monday’s trading, the company is valued at $14 billion.
In connection with the offering, X-Energy Inc. (NASDAQ:XE) granted its underwriters a 30-day option to purchase up to an additional 6.6 million shares.
If fully subscribed, this would increase its offer by another $152.68 million, for a total of $1.169 billion.
X-Energy Inc. (NASDAQ:XE) is a leading developer of advanced small modular nuclear reactors and fuel technology for clean energy generation.
In 2024, it earned the backing of e-commerce giant Amazon by being both an investor and a client, as the latter ramps up its plans to secure energy services from small modular reactors.
It also earned the backing of Cathie Wood’s Ark Invest, following the latter’s $120 million investment in the company.
While we acknowledge the potential of XE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than XE and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
